Highlights
Total revenue was
- Subscription revenue from patent risk management services—including insurance—was
$62.3 million , compared to$62.4 million in the prior year period. - Discovery services revenue was
$21.1 million , compared to$18.0 million in the prior year period.
"RPX posted a solid third quarter, with results exceeding expectations in both our patent risk management and discovery services businesses, along with increasing cash flow,"
Summary Results
GAAP net income for the third quarter was
Non-GAAP net income for the third quarter, which excludes stock-based compensation, the amortization of acquired intangibles, fair value adjustments on deferred payment obligations, gains on extinguishment of deferred payment obligations, realized losses on exchange of short-term investments, and their related tax effects, was
Non-GAAP adjusted EBITDA was
As of
Net patent acquisition spend during the quarter totaled
As of
Quarterly Dividend and Repayment of Term Facility
The Company also announced that its Board of Directors had approved a regular quarterly cash dividend of
In addition, the Company announced that it will be repaying the approximately
"These changes to our capital structure reflect the Board's confidence in the long term opportunity for RPX and reinforce its commitment to delivering value to shareholders, even as we continue investing to grow the business," said
Business Outlook
This outlook reflects the Company's current and preliminary view and may be subject to change. Please see the paragraph regarding "Forward-Looking Statements" at the end of this news release.
The Company provided the following business outlook for the fourth quarter of fiscal 2017:
Subscription and Discovery revenue[1] |
| |
Fee-related revenue |
| |
Total revenue |
| |
Operating income (non-GAAP) |
| |
Net income (non-GAAP) |
| |
Consolidated adjusted EBITDA (non-GAAP) |
| |
Effective tax rate (non-GAAP) |
35% | |
Weighted-average diluted shares outstanding |
50 million |
The Company provided the following updated business outlook for the full year 2017:
Subscription revenue[1] |
| |
Discovery revenue |
| |
Fee-related revenue |
| |
Total revenue |
| |
Cost of revenue (non-GAAP) |
| |
SG&A (non-GAAP) |
| |
Operating income (non-GAAP) |
| |
Net income (non-GAAP) |
| |
Patent risk management adjusted EBITDA (non-GAAP) |
| |
Discovery services adjusted EBITDA (non-GAAP) |
| |
Total adjusted EBITDA (non-GAAP) |
| |
Net patent spend |
| |
Consolidated adjusted EBITDA less net patent spend (non-GAAP) |
| |
Effective tax rate (non-GAAP) |
35% | |
Weighted-average diluted shares outstanding |
50 million |
The Company provided the following updated supplemental information regarding amortization expense for the full year 2017:
Amortization of patent assets acquired through |
| |
Amortization of patent assets to be acquired during fiscal 2017 |
| |
Total amortization of patent assets |
| |
Amortization of acquired intangible assets[2] |
|
———————— | |
[1] |
Subscription revenue is comprised of revenue generated from membership subscription services, premiums earned, net of ceding commissions, from insurance policies, and management fees related to the Company's insurance business. |
[2] |
RPX excludes amortization expense related to intangible assets (other than patents) acquired in conjunction with the acquisition of businesses from its non-GAAP financial measures. |
The above outlook is forward-looking. Actual results may differ materially. The Company is not able, at this time, to provide a forward-looking reconciliation to GAAP outlook for the non-GAAP financial metric outlook it has provided above for the fourth quarter and full year 2017 because of the difficulty of estimating certain items that are excluded from the non-GAAP financial metrics, including those items listed in "Use of Non-GAAP Financial Information" below, the effect of which may be significant. Please refer to the information under the caption "Use of Non-GAAP Financial Information" below.
Conference Call
RPX management will host a conference call and live webcast for analysts and investors at
The conference call will be webcast and investors will be able to access the webcast and slide presentation from the "Investor Relations" section of the company's website at www.rpxcorp.com. A replay of the webcast will be available online at the aforementioned website following the conclusion of the conference call.
About RPX
As of September 30, 2017, RPX had invested over $2 billion to acquire more than 18,500 US and international patent assets and rights on behalf of more than 325 clients in eight key sectors: automotive, consumer electronics and PCs, E-commerce and software, financial services, media content and distribution, mobile communications and devices, networking, and semiconductors.
RPX subsidiary Inventus is a leading international discovery management provider focused on reducing the costs and risks associated with the discovery process through the effective use of technology solutions. Inventus has been providing litigation support services to corporate legal departments, law firms and government agencies since 1991.
Use of Non-GAAP Financial Information
This news release dated
To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. Management is excluding from some or all of its non-GAAP operating results (1) stock-based compensation expenses (inclusive of related employer payroll taxes), (2) the amortization of acquired intangible assets (other than patents), (3) fair value adjustments on deferred payment obligations, (4) gains on extinguishment of deferred payment obligations, (5) other-than-temporary impairment on short-term investments, (6) realized losses on exchange of short-term investments, and (7) their related tax effects.
Management uses these non-GAAP measures to evaluate the Company's financial results and trends, allocate internal resources, prepare and approve our annual budget, develop short- and long-term operating plans, assess the health of our business and determine company-wide incentive compensation. Management believes these non-GAAP measures may prove useful to investors who wish to consider the impact of certain items when comparing the Company's financial performance with that of other companies. The adjustments to the Company's GAAP results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends and performance.
There are limitations in using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are adjusted to calculate our non-GAAP financial measures. Management compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in our public disclosures.
The presentation of additional information should not be considered in isolation or as a substitute for or superior to financial results determined in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measure and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
This news release and its attachments contain forward-looking statements within the meaning of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include the statements by management, statements regarding RPX's future financial performance as well as any statements regarding the Company's strategic and operational plans. The Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may contribute to such differences include, among others, the success of the Company's new initiatives, changes in our subscription fee rates, changes in the accounting treatment associated with how we recognize revenue under subscription agreements, and the Company's ability to attract new clients and retain existing clients with respect to our patent risk management and discovery services. Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "target," "will," "would," and similar expressions or variations intended to identify forward-looking statements. More information about potential factors that could affect the Company's business and financial results is contained in the Company's most recent annual report on Form 10-K, its quarterly reports on Form 10-Q, and the Company's other filings with the SEC. The Company does not intend, and undertakes no duty, to update any forward-looking statements to reflect future events or circumstances.
Contacts:
Investor Relations |
Media Relations |
|
|
|
|
+1 415-445-3233 |
+1 415-852-3180 |
| ||||||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended | |||||||||||||||
2017 |
2016 |
2017 |
2016 | |||||||||||||
Revenue |
$ |
85,702 |
$ |
88,461 |
$ |
248,648 |
$ |
251,305 |
||||||||
Cost of revenue |
52,282 |
50,830 |
154,722 |
147,566 |
||||||||||||
Selling, general and administrative expenses |
22,517 |
23,615 |
66,762 |
76,414 |
||||||||||||
Operating income |
10,903 |
14,016 |
27,164 |
27,325 |
||||||||||||
Interest and other income (expense), net: |
||||||||||||||||
Interest income |
339 |
162 |
761 |
348 |
||||||||||||
Interest expense |
(981) |
(922) |
(2,838) |
(2,155) |
||||||||||||
Other income (expense), net |
730 |
(490) |
2,059 |
813 |
||||||||||||
Total interest and other income (expense), net |
88 |
(1,250) |
(18) |
(994) |
||||||||||||
Income before provision for income taxes |
10,991 |
12,766 |
27,146 |
26,331 |
||||||||||||
Provision for income taxes |
4,625 |
4,651 |
10,595 |
9,829 |
||||||||||||
Net income |
$ |
6,366 |
$ |
8,115 |
$ |
16,551 |
$ |
16,502 |
||||||||
Net income per share: |
||||||||||||||||
Basic |
$ |
0.13 |
$ |
0.16 |
$ |
0.34 |
$ |
0.32 |
||||||||
Diluted |
$ |
0.13 |
$ |
0.16 |
$ |
0.33 |
$ |
0.32 |
||||||||
Weighted-average shares used in computing net income per share: |
||||||||||||||||
Basic |
49,556 |
49,713 |
49,128 |
50,932 |
||||||||||||
Diluted |
50,317 |
50,247 |
49,887 |
51,462 |
| |||||||
Condensed Consolidated Balance Sheets | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
|
| ||||||
Assets |
|||||||
Current assets: |
|||||||
Cash and cash equivalents |
$ |
228,410 |
$ |
100,111 |
|||
Short-term investments |
39,045 |
90,877 |
|||||
Restricted cash |
513 |
500 |
|||||
Accounts receivable, net |
41,027 |
64,395 |
|||||
Prepaid expenses and other current assets |
10,248 |
4,524 |
|||||
Total current assets |
319,243 |
260,407 |
|||||
Patent assets, net |
148,507 |
212,999 |
|||||
Property and equipment, net |
5,691 |
6,948 |
|||||
Intangible assets, net |
51,067 |
56,050 |
|||||
|
159,434 |
151,322 |
|||||
Restricted cash, less current portion |
965 |
965 |
|||||
Deferred tax assets |
37,410 |
38,261 |
|||||
Other assets |
9,537 |
8,337 |
|||||
Total assets |
$ |
731,854 |
$ |
735,289 |
|||
Liabilities and stockholders' equity |
|||||||
Current liabilities: |
|||||||
Accounts payable |
$ |
3,081 |
$ |
3,197 |
|||
Accrued liabilities |
13,543 |
16,798 |
|||||
Deferred revenue |
99,259 |
118,856 |
|||||
Current portion of long-term debt |
8,349 |
6,474 |
|||||
Other current liabilities |
1,244 |
1,484 |
|||||
Total current liabilities |
125,476 |
146,809 |
|||||
Deferred revenue, less current portion |
3,680 |
11,552 |
|||||
Deferred tax liabilities |
3,819 |
4,023 |
|||||
Long-term debt, less current portion |
81,535 |
88,110 |
|||||
Other liabilities |
10,834 |
10,514 |
|||||
Total liabilities |
225,344 |
261,008 |
|||||
Stockholders' equity: |
|||||||
Common stock |
5 |
5 |
|||||
Additional paid-in capital |
374,213 |
360,462 |
|||||
Retained earnings |
139,250 |
130,249 |
|||||
Accumulated other comprehensive loss |
(6,958) |
(16,435) |
|||||
Total stockholders' equity |
506,510 |
474,281 |
|||||
Total liabilities and stockholders' equity |
$ |
731,854 |
$ |
735,289 |
| |||||||
Condensed Consolidated Statements of Cash Flows | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
Nine Months Ended | |||||||
2017 |
2016 | ||||||
Operating activities |
|||||||
Net income |
$ |
16,551 |
$ |
16,502 |
|||
Adjustments to reconcile net income to net cash provided by operating activities: |
|||||||
Depreciation and amortization |
128,278 |
129,312 |
|||||
Stock-based compensation |
10,875 |
14,097 |
|||||
Excess tax benefit from stock-based compensation |
— |
(90) |
|||||
Amortization of premium on investments |
1,139 |
1,564 |
|||||
Deferred income taxes |
799 |
(5,975) |
|||||
Unrealized foreign currency (gain) loss |
(1,709) |
2,006 |
|||||
Fair value adjustment on deferred payment obligations |
— |
(1,920) |
|||||
Gain on extinguishment of deferred payment obligation |
— |
(463) |
|||||
Realized loss on exchange of short-term investments |
— |
290 |
|||||
Other |
157 |
902 |
|||||
Changes in assets and liabilities, net of business acquired: |
|||||||
Accounts receivable |
24,787 |
(8,168) |
|||||
Prepaid expenses and other assets |
(6,630) |
(11,177) |
|||||
Accounts payable |
(225) |
(276) |
|||||
Accrued and other liabilities |
(3,239) |
(3,742) |
|||||
Deferred revenue |
(27,470) |
(13,063) |
|||||
Net cash provided by operating activities |
143,313 |
119,799 |
|||||
Investing activities |
|||||||
Purchases of investments |
(32,811) |
(62,955) |
|||||
Maturities of investments |
83,335 |
48,073 |
|||||
Sales of investments |
— |
145,925 |
|||||
Business acquisition, net of cash acquired |
— |
(228,453) |
|||||
Decrease (increase) in restricted cash |
(13) |
427 |
|||||
Purchases of property and equipment |
(1,079) |
(3,004) |
|||||
Acquisitions of patent assets |
(54,492) |
(71,021) |
|||||
Net cash used in investing activities |
(5,060) |
(171,008) |
|||||
Financing activities |
|||||||
Proceeds from issuance of term debt |
— |
100,000 |
|||||
Payments of debt issuance costs |
— |
(2,003) |
|||||
Repayment of principal on term debt |
(5,000) |
(2,500) |
|||||
Deferred acquisition payment |
— |
(1,320) |
|||||
Proceeds from exercise of stock options |
5,964 |
3,657 |
|||||
Taxes paid related to net-share settlements of restricted stock units |
(4,526) |
(3,135) |
|||||
Excess tax benefit from stock-based compensation |
— |
90 |
|||||
Payments of capital leases |
(278) |
(352) |
|||||
Repurchase of common stock |
(6,629) |
(50,752) |
|||||
Net cash provided by (used in) financing activities |
(10,469) |
43,685 |
|||||
Foreign-currency effect on cash and cash equivalents |
515 |
(291) |
|||||
Net increase (decrease) in cash and cash equivalents |
128,299 |
(7,815) |
|||||
Cash and cash equivalents at beginning of period |
100,111 |
94,983 |
|||||
Cash and cash equivalents at end of period |
$ |
228,410 |
$ |
87,168 |
| ||||||||||||||||
Reconciliation of GAAP to Non-GAAP Net Income Per Share | ||||||||||||||||
(in thousands, except per share data) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended | |||||||||||||||
2017 |
2016 |
2017 |
2016 | |||||||||||||
Net income |
$ |
6,366 |
$ |
8,115 |
$ |
16,551 |
$ |
16,502 |
||||||||
Stock-based compensation[1] |
3,857 |
4,341 |
11,211 |
14,339 |
||||||||||||
Amortization of acquired intangible assets[2] |
2,110 |
2,457 |
6,784 |
7,209 |
||||||||||||
Fair value adjustment on deferred payment obligations[3] |
— |
— |
— |
(1,920) |
||||||||||||
Gain on extinguishment of deferred payment obligations[3] |
— |
— |
— |
(463) |
||||||||||||
Realized loss on exchange of short-term investments[3] |
— |
— |
— |
188 |
||||||||||||
Income tax adjustments[4] |
(1,471) |
(2,216) |
(4,874) |
(6,311) |
||||||||||||
Non-GAAP net income |
$ |
10,862 |
$ |
12,697 |
$ |
29,672 |
$ |
29,544 |
||||||||
Non-GAAP net income per share: |
||||||||||||||||
Basic |
$ |
0.22 |
$ |
0.26 |
$ |
0.60 |
$ |
0.58 |
||||||||
Diluted |
$ |
0.22 |
$ |
0.25 |
$ |
0.59 |
$ |
0.57 |
||||||||
Weighted-average shares used in computing non-GAAP net income per share: |
||||||||||||||||
Basic |
49,556 |
49,713 |
49,128 |
50,932 |
||||||||||||
Diluted |
50,317 |
50,247 |
49,887 |
51,462 |
| ||||||||||||||||
Reconciliation of GAAP to Non-GAAP Cost of Revenue | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended | |||||||||||||||
2017 |
2016 |
2017 |
2016 | |||||||||||||
Cost of revenue |
$ |
52,282 |
$ |
50,830 |
$ |
154,722 |
$ |
147,566 |
||||||||
Stock-based compensation[1] |
(126) |
— |
(347) |
— |
||||||||||||
Amortization of acquired intangible assets[2] |
(497) |
(548) |
(1,553) |
(1,592 |
||||||||||||
Non-GAAP cost of revenue |
$ |
51,659 |
$ |
50,282 |
$ |
152,822 |
$ |
145,974 |
| ||||||||||||||||
Reconciliation of GAAP to Non-GAAP Selling, General and Administrative Expenses | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended | |||||||||||||||
2017 |
2016 |
2017 |
2016 | |||||||||||||
Selling, general and administrative expenses |
$ |
22,517 |
$ |
23,615 |
$ |
66,762 |
$ |
76,414 |
||||||||
Stock-based compensation[1] |
(3,731) |
(4,341) |
(10,864) |
(14,339 |
||||||||||||
Amortization of acquired intangible assets[2] |
(1,613) |
(1,909) |
(5,231) |
(5,617 |
||||||||||||
Non-GAAP selling, general and administrative expenses |
$ |
17,173 |
$ |
17,365 |
$ |
50,667 |
$ |
56,458 |
| ||||||||||||||||
Reconciliation of GAAP to Non-GAAP Interest and Other Income (Expense), Net | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended | |||||||||||||||
2017 |
2016 |
2017 |
2016 | |||||||||||||
Interest and other income (expense), net |
$ |
88 |
$ |
(1,250) |
$ |
(18) |
$ |
(994) |
||||||||
Fair value adjustment on deferred payment obligation[3] |
— |
— |
— |
(1,920) |
||||||||||||
Gain on extinguishment of deferred payment obligations[3] |
— |
— |
— |
(463) |
||||||||||||
Realized loss on exchange of short-term investments[3] |
— |
— |
— |
188 |
||||||||||||
Non-GAAP interest and other income (expense), net |
$ |
88 |
$ |
(1,250) |
$ |
(18) |
$ |
(3,189) |
| |||||||||||||||
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA Less Net Patent Spend | |||||||||||||||
(in thousands) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended |
Nine Months Ended | ||||||||||||||
2017 |
2016 |
2017 |
2016 | ||||||||||||
Net income |
$ |
6,366 |
$ |
8,115 |
$ |
16,551 |
$ |
16,502 |
|||||||
Provision for income taxes |
4,625 |
4,651 |
10,595 |
9,829 |
|||||||||||
Interest and other (income) expense, net |
(88) |
1,250 |
18 |
994 |
|||||||||||
Stock-based compensation[1] |
3,857 |
4,341 |
11,211 |
14,339 |
|||||||||||
Depreciation and amortization |
42,423 |
43,725 |
128,278 |
129,312 |
|||||||||||
Non-GAAP adjusted EBITDA[5] |
57,183 |
62,082 |
166,653 |
170,976 |
|||||||||||
Net patent spend |
(12,990) |
(34,800) |
(54,575) |
(71,934 |
|||||||||||
Non-GAAP adjusted EBITDA less net patent spend |
$ |
44,193 |
$ |
27,282 |
$ |
112,078 |
$ |
99,042 |
| ||||||||
Additional Metrics | ||||||||
(in thousands, except client data) | ||||||||
(unaudited) | ||||||||
Three Months Ended | ||||||||
Operating Metrics |
2017 |
2016 | ||||||
Gross patent spend |
$ |
41,490 |
$ |
98,380 |
||||
Net patent spend |
$ |
12,990 |
$ |
34,800 |
||||
As of and for the Three Months | ||||||||
Financial Metrics |
2017 |
2016 | ||||||
Subscription revenue[6] |
$ |
62,346 |
$ |
62,414 |
||||
Discovery revenue |
21,080 |
17,987 |
||||||
Fee-related revenue |
2,276 |
8,060 |
||||||
Total revenue |
$ |
85,702 |
$ |
88,461 |
||||
Cash, cash equivalents and short-term investments |
$ |
267,455 |
$ |
182,707 |
||||
Deferred revenue, current and non-current |
$ |
102,939 |
$ |
102,691 |
[1] |
RPX excludes stock-based compensation and related employer payroll taxes from its non-GAAP financial measures. |
[2] |
RPX excludes amortization expense related to intangible assets (other than patents) acquired in conjunction with the acquisition of businesses from its non-GAAP financial measures. |
[3] |
RPX excludes fair value adjustments and gains on extinguishment related to its deferred payment obligations and realized losses on exchanges of short-term investments from its non-GAAP financial measures. |
[4] |
Amount reflects income taxes associated with the above noted non-GAAP exclusions. |
[5] |
RPX calculates non-GAAP adjusted EBITDA as GAAP earnings before other income or expenses, net, provision for income taxes, depreciation, amortization, and stock-based compensation expenses (inclusive of related employer payroll taxes). |
[6] |
Subscription revenue is comprised of revenue generated from membership subscription services, premiums earned, net of ceding commissions, from insurance policies, and management fees related to its insurance business. |
View original content with multimedia:http://www.prnewswire.com/news-releases/rpx-announces-third-quarter-2017-financial-results-300545746.html
SOURCE
News Provided by Acquire Media